Most of the studies support the suggestion that microvascular abnormality is associated with depression, whilst other works contradict this idea. It seems plausible that microvascular abnormality is only relevant in some subtypes of depression, for example, depression due to a general medical condition like atherosclerosis, myocardial ischemia, hypertension, diabetes mellitus or inflammation, late-life depression, or pharmacoresistant depression. For details and references, see
Table 1.
| Type of Studies | Authors and Year |
|---|
| Studies supporting the idea that microvascular abnormality is associated with depression | Ballard et al., 2000; Sinka et al., 2012; Nguyen et al., 2010; Hajjar et al., 2011; Kim et al., 2011; Li et al., 2013; Wolfson et al., 2013; Meier et al., 2014; Tchalla et al., 2015 |
| Studies contradicting the idea that microvascular abnormality is associated with depression | Thomas et al., 2001; Santos et al., 2010; Sun et al., 2007; Nguyen et al., 2008 |
| Studies suggesting that microvascular abnormality is only relevant in some subtypes of depression, for example, depression due to a general medical condition like atherosclerosis, myocardial ischemia, hypertension, diabetes mellitus or inflammation | Thomas et al., 2001; Santos et al., 2009; Vaccarino et al., 2009; Nguyen et al., 2010; Hajjar et al., 2011; Kim et al., 2011; Santos et al., 2012; Wolfson et al., 2013; Tchalla et al., 2015; Gorska-Ciebiada et al., 2015 |
| Studies assuming that microvascular abnormality is only relevant in late-life depression | Ballard et al., 2000; Thomas et al., 2001; Patankar et al., 2007; Santos et al., 2009; Hajjar et al., 2011; Kim et al., 2011; Sinka et al., 2012; Wolfson et al., 2013; Tchalla et al., 2015; Gorska-Ciebiada et al., 2015 |
| Study presuming that microvascular abnormality is only significant in pharmacoresistant depression | Patankar et al., 2007 |
Authors of several review articles tried to depict biological mechanisms by which microvascular abnormality is interconnected with depression (
Figure 1). Camus et al. (2004) overviewed 37 articles. Among other genetic findings, a preliminary study revealed that the serotonin transporterl-linked polymorphism (5-HTTLPR) could increase the risk of geriatric depression. Literary, data suggest that the dual implication for serotonin in both depression and thrombogenesis supports the view that serotoninmediated platelet activation serves as a plausible pathophysiological process linking depression and vascular diseases. Apart from this, the allelic combination of two genes linked with an increase in the risk of myocardial infarction (angiotensin I converting enzyme and G-protein beta 3 subunit) was shown to heighten the vulnerability to depressive disorder (
5). Camus et al. suggested three general potential pathways of association of vascular diseases and depression: 1. Direct influence of arteriosclerosis on the incidence of depression; 2. Direct impact of depression on the cardiovascular system; 3. Either a shared common pathophysiological process or genetic background between depression and vascular disease.
Biological Mechanisms of Depression With Microvascular Abnormalities
According to Santos et al. (2009; 2012), depression may be induced either by the interrupting biogenic amine pathways through ischemic lesions in the brain, or the negative effect of proinflammatory cytokines released as a response to acute cerebral ischemia. There is also a positive relationship between the presence of the ApoE ε4 allele and an increase in the risk of late-life depression. There exist three main etiopathogenetic pathways which have been implicated in both cardiovascular pathologies and latelife depression: hyperhomocysteinemia, endothelial dysfunction and inflammation. The authors also state that a vascular stress-induced decrease in the neurogenesis of the hippocampal dentate gyrus may bring on depressive episodes(
9,
29). Disturbed adult neurogenesis, possibly leading to a malfunctioning hippocampus, may add to the cognitive deficits and reduced hippocampal volumes seen in depressed patients.
Several avenues for further research into microvascular pathology in clinical depression, which may also include the assessment of retinal vessels, are possible:
- Whole-genome association studies identifying the genes responsible for microvascular changes, depression and their overlap, including their epigenetic status in various ethnic groups
- A more intense evaluation of the role of inflammation biomarkers in the development of depression
- More precise identification of depression subtypes in which microvascular abnormality is significant
- Exploration of unipolar, bipolar and adjustment depression separately as of a possible microvascular pathology
- Research aimed at finding specific brain loci in which microvascular disorders may trigger depression
- Looking for psychosocial variables important in the development of the microvascular subtype of depression
- Gene-Environment Wide Interaction Studies (GEWIS) in which multiple gene vs gene, gene vs environment and environment vs environment interactions are evaluated simultaneously, taking the statistical problem of multiple comparisons into account
- Longitudinal studies in depressed patients focused on their microvascular pathology and a possible relationship to the clinical state
- Psychiatric and ophthalmological examination of offspring of the patients with depression and microvascular pathology
- Psychopharmacological studies of antidepressants and other medications (e.g. anti-inflammatory drugs) efficient in the treatment of depression accompanied by microvascular abnormality
From the clinical point of view, it seems to be reasonable to actively search for physical illnesses, which contribute to depression associated with a microvascular pathology, (e.g. hypertension, diabetes, and inflammation) in depressed patients, and to treat them sufficiently.